Leonardo Brustolin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Leonardo Brustolin has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Dolores Fregona
Department of Chemical Sciences, University of Padova, Padova, Italy
4 shared publications - Federica Chiara
Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy
3 shared publications A. Gambalunga
Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy
2 shared publicationsA. Trevisan
Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy
2 shared publications- Chiara Nardon
Biomedical Chemistry Lab, Department of Biotechnology, University of Verona, Strada le Grazie 15, 37134, Verona, Italy
2 shared publications Alberto Gambalunga
Department of Cardiac, Thoracic, and Vascular Sciences, University of Padova Via Giustiniani 2, 35128, Padova, Italy
1 shared publication
Latest Publications
- 27 September 2019
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 48 (42) , 16017-16025
Au( iii )-Proline derivatives exhibiting selective antiproliferative activity against HepG2/SB3 apoptosis-resistant cancer cells
This paper deals with the combination of a proline-based moiety with biologically active gold centers in the oxidation states +1 and +3. In particular, six Au(I)/(III)–proline dithiocarbamato (DTC) complexes with general formulae [AuI 2(DTC)2] and [AuIIIX2(DTC)] (X = Cl, Br) are reported here. After the synthesis of the ligand and the complexes, all derivatives were characterized via several techniques and tested for their stability in DMSO/water media. This study was focused on the demonstration of a peculiar behavior of Au(III)–DTC species in solution. Finally, the complexes were screened for their antiproliferative activity against 2 human cancer cell lines, namely HepG2 and HepG2/SB3, taken as models of hepatocellular carcinoma. The latter, chosen for its aggressiveness due to the upregulation of the anti-apoptotic protein SerpinB3, was selectively inhibited in terms of growth by some Au(III)–DTC complexes.
- 27 September 2019
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 48 (42) , 16017-16025
Au( iii )-Proline derivatives exhibiting selective antiproliferative activity against HepG2/SB3 apoptosis-resistant cancer cells
This paper deals with the combination of a proline-based moiety with biologically active gold centers in the oxidation states +1 and +3. In particular, six Au(I)/(III)–proline dithiocarbamato (DTC) complexes with general formulae [AuI 2(DTC)2] and [AuIIIX2(DTC)] (X = Cl, Br) are reported here. After the synthesis of the ligand and the complexes, all derivatives were characterized via several techniques and tested for their stability in DMSO/water media. This study was focused on the demonstration of a peculiar behavior of Au(III)–DTC species in solution. Finally, the complexes were screened for their antiproliferative activity against 2 human cancer cell lines, namely HepG2 and HepG2/SB3, taken as models of hepatocellular carcinoma. The latter, chosen for its aggressiveness due to the upregulation of the anti-apoptotic protein SerpinB3, was selectively inhibited in terms of growth by some Au(III)–DTC complexes.
- 1 January 2017
- Published by Elsevier in Journal of Inorganic Biochemistry
- Vol. 166, 76-86
Ru(III) anticancer agents with aromatic and non-aromatic dithiocarbamates asligands: Loading into nanocarriers and preliminary biological studies
- 1 January 2017
- Published by Elsevier in Journal of Inorganic Biochemistry
- Vol. 166, 76-86
Ru(III) anticancer agents with aromatic and non-aromatic dithiocarbamates asligands: Loading into nanocarriers and preliminary biological studies
- 1 December 2016
- Published by Elsevier in Journal of Inorganic Biochemistry
- Vol. 165, 159-169
Ru(III) anticancer agents with aromatic and non-aromatic dithiocarbamates as ligands: Loading into nanocarriers and preliminary biological studies
- 1 December 2016
- Published by Elsevier in Journal of Inorganic Biochemistry
- Vol. 165, 159-169
Ru(III) anticancer agents with aromatic and non-aromatic dithiocarbamates as ligands: Loading into nanocarriers and preliminary biological studies
- 25 January 2016
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 8 (2) , 211-226
Is Matching Ruthenium with Dithiocarbamato Ligands a Potent Chemotherapeutic Weapon in Oncology?
In the last years, several metal-based compounds have been designed and biologically investigated worldwide in order to obtain chemotherapeutics with a better toxicological profile and comparable or higher antiblastic activity than the clinically-established platinum-based drugs. In this context, researchers have addressed their attention to alternative nonplatinum derivatives able to maximize the anticancer activity of the new drugs and to minimize the side effects. Among them, a number of ruthenium complexes have been developed, including the compounds NAMI-A and KP1019, now in clinical trials. Here, we report the results collected so far for a particular class of ruthenium complexes – the ruthenium(II/III)-dithiocarbamates – which proved more potent than cisplatin in vitro, even at nanomolar concentrations, against a wide panel of human tumor cell lines.
- 25 January 2016
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 8 (2) , 211-226
Is Matching Ruthenium with Dithiocarbamato Ligands a Potent Chemotherapeutic Weapon in Oncology?
In the last years, several metal-based compounds have been designed and biologically investigated worldwide in order to obtain chemotherapeutics with a better toxicological profile and comparable or higher antiblastic activity than the clinically-established platinum-based drugs. In this context, researchers have addressed their attention to alternative nonplatinum derivatives able to maximize the anticancer activity of the new drugs and to minimize the side effects. Among them, a number of ruthenium complexes have been developed, including the compounds NAMI-A and KP1019, now in clinical trials. Here, we report the results collected so far for a particular class of ruthenium complexes – the ruthenium(II/III)-dithiocarbamates – which proved more potent than cisplatin in vitro, even at nanomolar concentrations, against a wide panel of human tumor cell lines.
- Open Access
- 19 February 2015
- Published by Wiley in ChemistryOpen
- Vol. 4 (2) , 183-191
Gold(III)–pyrrolidinedithiocarbamato Derivatives as Antineoplastic Agents
Transition metals offer many possibilities in developing potent chemotherapeutic agents. They are endowed with a variety of oxidation states, allowing for the selection of their coordination numbers and geometries via the choice of proper ligands, leading to the tuning of their final biological properties. We report here on the synthesis, physico‐chemical characterization, and solution behavior of two gold(III) pyrrolidinedithiocarbamates (PDT), namely [AuIIIBr2(PDT)] and [AuIIICl2(PDT)]. We found that the bromide derivative was more effective than the chloride one in inducing cell death for several cancer cell lines. [AuIIIBr2(PDT)] elicited oxidative stress with effects on the permeability transition pore, a mitochondrial channel whose opening leads to cell death. More efficient antineoplastic strategies are required for the widespread burden that is cancer. In line with this, our results indicate that [AuIIIBr2(PDT)] is a promising antineoplastic agent that targets cellular components with crucial functions for the survival of tumor cells.
- 19 February 2015
- Published by Wiley in ChemistryOpen
- Vol. 4 (2) , 183-191
Open AccessGold(III)–pyrrolidinedithiocarbamato Derivatives as Antineoplastic Agents
Transition metals offer many possibilities in developing potent chemotherapeutic agents. They are endowed with a variety of oxidation states, allowing for the selection of their coordination numbers and geometries via the choice of proper ligands, leading to the tuning of their final biological properties. We report here on the synthesis, physico‐chemical characterization, and solution behavior of two gold(III) pyrrolidinedithiocarbamates (PDT), namely [AuIIIBr2(PDT)] and [AuIIICl2(PDT)]. We found that the bromide derivative was more effective than the chloride one in inducing cell death for several cancer cell lines. [AuIIIBr2(PDT)] elicited oxidative stress with effects on the permeability transition pore, a mitochondrial channel whose opening leads to cell death. More efficient antineoplastic strategies are required for the widespread burden that is cancer. In line with this, our results indicate that [AuIIIBr2(PDT)] is a promising antineoplastic agent that targets cellular components with crucial functions for the survival of tumor cells.